Medical Technology Financings Over $400 million in May 2011

1 Min Read

Financings in medical technology are on an uptick for May 2011, even if the $107 million raised by the implantable defibrillator company Cameron Health is considered an anomaly.  There remains an impressive list of big financings that have come through this month, including $60 million to genome diagnostics company CardioDx, $30 million to neurology therapeutics company Neuronetics, $22 million to fibrin sealant company ProFibrix NV and the $20 million to surgical sealant company Lifebond.

Financings in medical technology are on an uptick for May 2011, even if the $107 million raised by the implantable defibrillator company Cameron Health is considered an anomaly.  There remains an impressive list of big financings that have come through this month, including $60 million to genome diagnostics company CardioDx, $30 million to neurology therapeutics company Neuronetics, $22 million to fibrin sealant company ProFibrix NV and the $20 million to surgical sealant company Lifebond.

The complete list of May 2011 financings in medical technologies is detailed at link (be sure to bookmark to capture financings through the end of the month).

    

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version